

Francesco Forconi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3454135/publications.pdf>

Version: 2024-02-01

268
papers

10,973
citations

36303

51
h-index

33894

99
g-index

272
all docs

272
docs citations

272
times ranked

9126
citing authors

#	ARTICLE	IF	CITATIONS
1	Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 663.	3.7	4
2	B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2022, 3, 37-49.	0.8	2
3	B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells. <i>Cellular Signalling</i> , 2022, 94, 110311.	3.6	5
4	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. <i>Blood</i> , 2022, 140, 630-643.	1.4	14
5	BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. <i>Cellular Signalling</i> , 2022, 96, 110358.	3.6	1
6	High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL. <i>Blood Advances</i> , 2022, 6, 5494-5504.	5.2	3
7	KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity. <i>Journal of Immunology</i> , 2022, 209, 379-390.	0.8	5
8	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 665.	12.8	9
9	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	7.2	28
10	DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity. <i>Scientific Reports</i> , 2021, 11, 11676.	3.3	4
11	Exploring the pathways to chronic lymphocytic leukemia. <i>Blood</i> , 2021, 138, 827-835.	1.4	20
12	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. <i>Blood</i> , 2021, 138, 1570-1582.	1.4	9
13	Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells. <i>Clinical Cancer Research</i> , 2021, 27, 5647-5659.	7.0	3
14	Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 6337-6349.	5.4	14
15	The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. <i>Frontiers in Oncology</i> , 2021, 11, 723722.	2.8	0
16	Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial. <i>Blood</i> , 2021, 138, 642-642.	1.4	26
17	Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance. <i>Blood</i> , 2021, 138, 3717-3717.	1.4	0
18	Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E. <i>Blood</i> , 2021, 138, 2411-2411.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial. <i>Blood</i> , 2021, 138, 2636-2636.	1.4	8
20	Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. <i>Leukemia</i> , 2020, 34, 462-477.	7.2	24
21	BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 640-644.	7.2	12
22	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 918-923.	2.5	19
23	Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells. <i>Clinical Cancer Research</i> , 2020, 26, 1700-1711.	7.0	13
24	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. <i>Lancet Haematology</i> , 2020, 7, e112-e121.	4.6	119
25	Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCLv). <i>British Journal of Haematology</i> , 2020, 191, 730-737.	2.5	14
26	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	1.4	86
27	Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. <i>Blood</i> , 2020, 136, 2918-2926.	1.4	67
28	IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. <i>Blood</i> , 2020, 135, 834-844.	1.4	23
29	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	3.5	64
30	Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. <i>Blood</i> , 2020, 135, 411-428.	1.4	17
31	Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. <i>Blood</i> , 2020, 136, 17-18.	1.4	11
32	Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials. <i>Journal of Clinical Oncology</i> , 2020, 38, e20011-e20011.	1.6	0
33	Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2020, 136, 36-37.	1.4	1
34	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2722-2729.	1.6	197
35	International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S278.	0.4	1
36	Hedgehog activation in CLL. <i>Blood</i> , 2019, 133, 2628-2630.	1.4	0

#	ARTICLE	IF	CITATIONS
37	INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A). Hematological Oncology, 2019, 37, 81-82.	1.7	1
38	Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the postâ€‹BCRâ€‹ inhibitor setting: a â€‹UKâ€‹ wide analysis. British Journal of Haematology, 2019, 185, 656-669.	2.5	53
39	Genome-wide promoter methylation of hairy cell leukemia. Blood Advances, 2019, 3, 384-396.	5.2	16
40	Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. Clinical Cancer Research, 2019, 25, 2503-2512.	7.0	23
41	PS1125â€‹LINKING MICROENVIRONMENTAL SIGNALS TO METABOLIC SWITCHES AND IBRUTINIB RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA. HemaSphere, 2019, 3, 509-510.	2.7	1
42	Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia. Blood, 2019, 134, 1740-1740.	1.4	1
43	Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets. Blood, 2019, 134, 1505-1505.	1.4	1
44	High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients. Blood, 2019, 134, 1752-1752.	1.4	4
45	PF526 STRUCTURAL AND FUNCTIONAL VARIABILITY OF THE TUMOR Bâ€‹CELL RECEPTOR INDICATES A ROLE FOR ENVIRONMENTAL INFLUENCES ON BEHAVIOR OF MANTLE CELL LYMPHOMAS. HemaSphere, 2019, 3, 215-216.	2.7	0
46	Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia. Blood, 2019, 134, 479-479.	1.4	1
47	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica, 2018, 103, 1209-1217.	3.5	30
48	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. Leukemia and Lymphoma, 2018, 59, 423-433.	1.3	7
49	Acalabrutinib in Patients (pts) with Waldenstr�m Macroglobulinemia (WM). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S285-S286.	0.4	1
50	Five years of ibrutinib in CLL. Blood, 2018, 131, 2280-2281.	1.4	3
51	Shaving Is an Epiphenomenon of Type I and II Anti-CD20â€‹Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy. Journal of Immunology, 2018, 201, 1211-1221.	0.8	20
52	Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. Blood, 2018, 132, 182-182.	1.4	20
53	Lymphoma-Specific Subversion of B-Cell Receptor Signaling By Macrophage Lectins. Blood, 2018, 132, 2865-2865.	1.4	2
54	NOTCH1 Stabilization By PEST Mutations Enhances IgM-Mediated Activity in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 1832-1832.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology, 2018, 36, 7501-7501.	1.6	11
56	Abstract 1871: Development of pelorol analogues to activate the SHIP1 lipid phosphatase; a novel paradigm to suppress B-cell receptor signaling in human B-cell cancers. , 2018, , .		1
57	Acquisition of Mannoses on the Surface Immunoglobulin Binding Site Reveals Functional Status and Cell of Origin in Diffuse Large B Cell Lymphomas. Blood, 2018, 132, 677-677.	1.4	0
58	Immunoglobulin Variable Region Gene Sequences Reveal N-Glycosylation Motifs As an Early and Stable Event in Follicular Lymphoma Pathology. Blood, 2018, 132, 4101-4101.	1.4	0
59	STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. Cancer Research, 2017, 77, 3619-3631.	0.9	69
60	Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. Haematologica, 2017, 102, 968-971.	3.5	28
61	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood, 2017, 129, 553-560.	1.4	193
62	Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S11-S12.	0.4	0
63	PI3K γ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis. Leukemia, 2017, 31, 1423-1433.	7.2	12
64	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 2313-2324.	7.0	51
65	IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus. Leukemia, 2017, 31, 1686-1694.	7.2	28
66	Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. Blood, 2016, 128, 816-826.	1.4	54
67	IL-4 enhances expression and function of surface IgM in CLL cells. Blood, 2016, 127, 3015-3025.	1.4	76
68	Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. Blood, 2016, 127, 449-457.	1.4	56
69	Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. Leukemia, 2016, 30, 2179-2186.	7.2	69
70	The outcome of Chronic lymphocytic leukaemia patients with 97% <i>IGHV</i> gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity. British Journal of Haematology, 2016, 173, 127-136.	2.5	19
71	The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. Leukemia, 2016, 30, 351-360.	7.2	88
72	Global and MYC-Specific Translation Is Enhanced in Activated Chronic Lymphocytic Leukemia Cells Carrying NOTCH1 C.7541_7542delct Mutations. Blood, 2016, 128, 970-970.	1.4	2

#	ARTICLE	IF	CITATIONS
73	PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2 γ phosphorylation in established cell lines and primary human leukemia cells. <i>Oncotarget</i> , 2016, 7, 74807-74819.	1.8	7
74	Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression. <i>Blood</i> , 2016, 128, 351-351.	1.4	0
75	A Distributed International Patient Data Registry for Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5986-5986.	1.4	0
76	PI3K γ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis. <i>Blood</i> , 2016, 128, 3241-3241.	1.4	0
77	Early Enhancement of IgM Expression and Signaling Capacity during Ibrutinib Therapy in CLL Patients. <i>Blood</i> , 2016, 128, 4381-4381.	1.4	0
78	Chemical Activation of the SHIP1 Inositol Lipid Phosphatase: A Novel Therapeutic Strategy to Suppress B-Cell Receptor Signaling and CXCR4 Expression in Malignant Human B Cells. <i>Blood</i> , 2016, 128, 2037-2037.	1.4	1
79	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	1.4	53
80	The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the E μ -TCL1 mouse model. <i>Blood</i> , 2015, 125, 4032-4041.	1.4	34
81	Perturbation of the normal immune system in patients with CLL. <i>Blood</i> , 2015, 126, 573-581.	1.4	290
82	Three years of ibrutinib in CLL. <i>Blood</i> , 2015, 125, 2455-2456.	1.4	5
83	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	1.4	197
84	Higher levels of reactive oxygen species are associated with anergy in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, e265-e268.	3.5	9
85	Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3K γ inhibition. <i>Leukemia</i> , 2015, 29, 744-747.	7.2	20
86	Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing. <i>Clinical Cancer Research</i> , 2015, 21, 4174-4183.	7.0	129
87	The Syk/Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling. <i>Blood</i> , 2015, 126, 1716-1716.	1.4	3
88	IL-10 Production By CLL Cells Is Enhanced in the Anergic IGHV Mutated Subset and Associates with Reduced DNA Methylation of the IL-10 Locus. <i>Blood</i> , 2015, 126, 2917-2917.	1.4	0
89	Biological Significance of B Cell Receptor Mediated Regulation of Autophagy in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 4130-4130.	1.4	0
90	Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 365-365.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Variant B Cell Receptor Isotype Functions Differ in Hairy Cell Leukemia with Mutated BRAF and IGHV Genes. PLoS ONE, 2014, 9, e86556.	2.5	8
92	Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. PLoS ONE, 2014, 9, e98818.	2.5	33
93	The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica, 2014, 99, 1138-1148.	3.5	87
94	The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia. Seminars in Hematology, 2014, 51, 158-167.	3.4	42
95	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Experimental Hematology, 2014, 42, 126-136.e1.	0.4	23
96	Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. Blood, 2014, 124, 3101-3109.	1.4	34
97	HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. Haematologica, 2014, 99, 888-896.	3.5	43
98	Characterising the Burden of Chronic Lymphocytic Leukemia in Fludarabine-Ineligible Patients in Spain, Italy, and the United Kingdom (UK): A Retrospective Observational Study. Blood, 2014, 124, 2646-2646.	1.4	1
99	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. ELife, 2014, 3, .	6.0	43
100	Surface IgM Levels Independently Influence Clinical Behavior and Associate with Altered Phenotype and Genetics in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 830-830.	1.4	0
101	Increased Reactive Oxygen Species and the B-Cell Receptor in Chronic Lymphocytic Leukemia Signaling. Blood, 2014, 124, 3291-3291.	1.4	0
102	IL-4 Exerts Opposing Effects on Surface-IgM and CXCR4 Mediated Signalling in Chronic Lymphocytic Leukaemia. Blood, 2014, 124, 3299-3299.	1.4	0
103	Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications. Blood, 2014, 124, 76-76.	1.4	1
104	The Dual PI3K/mTOR Inhibitor PF-04691502 Induces Substantial Apoptosis in Chronic Lymphocytic Leukemia Cells in Vitro and Prolongs Survival in the Eµ-TCL1 Mouse Model. Blood, 2014, 124, 832-832.	1.4	0
105	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3300-3300.	1.4	0
106	Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. Annals of Oncology, 2013, 24, 1378-1384.	1.2	13
107	Promoter methylation patterns in Richter syndrome affect stem cell maintenance and cell cycle regulation and differ from de novo diffuse large B cell lymphoma. British Journal of Haematology, 2013, 163, 194-204.	2.5	19
108	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood, 2013, 122, 2673-2682.	1.4	208

#	ARTICLE	IF	CITATIONS
109	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood, 2013, 121, 1403-1412.	1.4	420
110	Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. Leukemia, 2013, 27, 241-245.	7.2	28
111	<i>MGA</i> , a suppressor of <i>MYC</i> , is recurrently inactivated in high risk chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1087-1090.	1.3	81
112	Genome-wide high resolution <i>scDNA</i> profiling of hairy cell leukaemia. British Journal of Haematology, 2013, 162, 566-569.	2.5	18
113	Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. Blood, 2013, 122, 2664-2672.	1.4	58
114	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood, 2013, 121, 4902-4905.	1.4	113
115	Tiacci E, Schiavoni G, Forconi F, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119(1):192-195.. Blood, 2013, 122, 1685-1685.	1.4	0
116	Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. Hematological Oncology, 2013, 31, 88-95.	1.7	25
117	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. Blood, 2013, 122, 77-77.	1.4	0
118	B Cell Receptor with Variant Surface Isotypes Transduce Functional Signals by Elevating Phospho-ERK1/2 Levels in Hairy Cell Leukemia with Mutant BRAF. Blood, 2013, 122, 1772-1772.	1.4	0
119	Genome-Wide Promoter Methylation Of Hairy Cell Leukemia (HCL). Blood, 2013, 122, 3757-3757.	1.4	0
120	Modulation of B Cell Receptor Signalling By IL-4 In Chronic Lymphocytic Leukaemia. Blood, 2013, 122, 4125-4125.	1.4	0
121	Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood, 2012, 119, 192-195.	1.4	166
122	The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells. Blood, 2012, 119, 2106-2109.	1.4	11
123	Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood, 2012, 119, 2854-2862.	1.4	257
124	S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis. Blood, 2012, 120, 4391-4399.	1.4	50
125	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. Haematologica, 2012, 97, 849-853.	3.5	14
126	Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood, 2012, 119, 521-529.	1.4	394

#	ARTICLE	IF	CITATIONS
127	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. <i>Hematological Oncology</i> , 2012, 30, 46-49.	1.7	20
128	Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. <i>International Journal of Cancer</i> , 2012, 130, 3006-3010.	5.1	28
129	Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array. <i>British Journal of Haematology</i> , 2012, 156, 354-357.	2.5	9
130	Different impact of <i>NOTCH1</i> and <i>SF3B1</i> mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2012, 158, 426-429.	2.5	90
131	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , 2012, 10, 18.	4.4	21
132	Large Genomic Aberrations Are Independent Prognosticators of A Shorter Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia (CLL) Patients with A Normal FISH. <i>Blood</i> , 2012, 120, 3906-3906.	1.4	2
133	Phenethyl Isothiocyanate (PEITC) Regulates Autophagy in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2906-2906.	1.4	0
134	Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 712-712.	1.4	0
135	In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1782-1782.	1.4	2
136	Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. <i>Leukemia and Lymphoma</i> , 2011, 52, 75-78.	1.3	53
137	Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis. <i>Leukemia and Lymphoma</i> , 2011, 52, 15-23.	1.3	8
138	Insight into the behavior of hairy cell leukemia by immunogenetic analysis. <i>Leukemia and Lymphoma</i> , 2011, 52, 103-107.	1.3	5
139	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , 2011, 117, 3391-3401.	1.4	316
140	Alternative methods of cladribine administration. <i>Leukemia and Lymphoma</i> , 2011, 52, 34-37.	1.3	18
141	<i>BRAF</i> Mutations in Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2011, 364, 2305-2315.	27.0	949
142	Analysis of the chronic lymphocytic leukemia coding genome: role of <i>NOTCH1</i> mutational activation. <i>Journal of Experimental Medicine</i> , 2011, 208, 1389-1401.	8.5	565
143	Mutations of the <i>SF3B1</i> splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. <i>Blood</i> , 2011, 118, 6904-6908.	1.4	342
144	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 117, 2405-2413.	1.4	30

#	ARTICLE	IF	CITATIONS
145	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	1.4	173
146	Bâ€cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the <i>IGHV3</i> subgroup gene usage. <i>British Journal of Haematology</i> , 2011, 153, 3-14.	2.5	30
147	A variant of the <i>LRP4</i> gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2011, 152, 284-294.	2.5	28
148	A pilot monocentric analysis of efficacy and safety of Fludarabineâ€Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 dysfunction. <i>British Journal of Haematology</i> , 2011, 154, 271-274.	2.5	3
149	Genomeâ€wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 154, 590-599.	2.5	40
150	The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: A retrospective multicentric GIMEMA experience. <i>American Journal of Hematology</i> , 2011, 86, 1007-1012.	4.1	47
151	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 633-643.	2.8	67
152	Lack of allelic exclusion by secondary rearrangements of tumour Bâ€cell receptor light chains in hairy cell leukaemia. <i>Hematological Oncology</i> , 2011, 29, 31-37.	1.7	5
153	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2011, 29, 91-99.	1.7	30
154	Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. <i>Hematological Oncology</i> , 2011, 29, 55-66.	1.7	35
155	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. <i>Blood</i> , 2011, 118, 294-294.	1.4	6
156	A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase.. <i>Journal of Clinical Oncology</i> , 2011, 29, 6629-6629.	1.6	2
157	Molecular Cytogenetics Analysis of 13q14 Biallelic Deletion in Chronic Lymphocytic Leukemia: A Study on 250 Patients. <i>Blood</i> , 2011, 118, 1454-1454.	1.4	0
158	Mutations of NOTCH1 Are An Independent Predictor of Survival in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 283-283.	1.4	0
159	A Prospective, Multi Center Phase II Study Evaluating Predictive Factors for Lenalidomide Treatment in Relapse or Refractory Chronic Lymphocytic Leukemia Patients (LE.P.RE.): Preliminary Results about the First 20 Enrolled Patients. <i>Blood</i> , 2011, 118, 1782-1782.	1.4	0
160	Disruption of BIRC3 associates with Fludarabine Chemorefractoriness in TP53 Wild Type Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 466-466.	1.4	0
161	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). <i>Blood</i> , 2011, 118, 263-263.	1.4	1
162	Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway. <i>Blood</i> , 2011, 118, 1359-1359.	1.4	17

#	ARTICLE	IF	CITATIONS
163	Mutations of the SF3B1 splicing Factor in Chronic Lymphocytic Leukemia: Association with Progression and Fludarabine-Refractoriness. Blood, 2011, 118, 464-464.	1.4	4
164	Hairy Cell Leukaemia Displaying Multiple Surface Immunoglobulin Isotypes Reveal a Functional B-Cell Receptor In Which Isotype Roles Differ. Blood, 2011, 118, 1567-1567.	1.4	0
165	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica, 2010, 95, 1792-1796.	3.5	91
166	The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood, 2010, 115, 71-77.	1.4	83
167	Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia. Blood, 2010, 115, 3726-3736.	1.4	47
168	Impact of the host genetic background on prognosis of chronic lymphocytic leukemia. Blood, 2010, 115, 1106-1107.	1.4	5
169	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. Leukemia and Lymphoma, 2010, 51, 822-838.	1.3	9
170	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood, 2010, 116, 584-592.	1.4	51
171	Genomic profiling of Richter's syndrome: recurrent lesions and differences with <i>de novo</i> diffuse large B-cell lymphomas. Hematological Oncology, 2010, 28, 62-67.	1.7	46
172	<i>IGHD3</i> fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. British Journal of Haematology, 2010, 149, 299-302.	2.5	1
173	<i>MDM4 (MDMX)</i> is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53^{wild} CLL with a poor cytotoxic response to Nutlin. British Journal of Haematology, 2010, 150, 237-239.	2.5	27
174	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. British Journal of Haematology, 2010, 151, 435-439.	2.5	20
175	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. Clinical Cancer Research, 2010, 16, 620-628.	7.0	44
176	Predicting the clinical course of Hodgkin lymphoma. Nature Reviews Clinical Oncology, 2010, 7, 1-1.	27.6	1
177	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). Blood, 2010, 116, 1371-1371.	1.4	2
178	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. Blood, 2010, 116, 2462-2462.	1.4	17
179	Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405. Blood, 2010, 116, 2471-2471.	1.4	2
180	SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. Blood, 2010, 116, 3611-3611.	1.4	4

#	ARTICLE	IF	CITATIONS
181	Analysis of Toxicity and Efficacy of Subcutaneous Cladribine at Reduced or Standard Doses (Five) Tj ETQq1 1 0.784314 rgBT /Overlock 1 by the Italian Cooperative Group on Hcl. Blood, 2010, 116, 701-701.	1.4	5
182	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 3578-3578.	1.4	0
183	Molecular History of Richter Syndrome: Origin From a Common Ancestor Cell Already Present at Chronic Lymphocytic Leukemia Diagnosis. Blood, 2010, 116, 2425-2425.	1.4	1
184	The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship. Blood, 2010, 116, 3601-3601.	1.4	0
185	Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.4	5
186	â€œEarly-FDG-PETâ€•but Not Macrophage Infiltration In Diagnostic Specimen Seems to Predict Clinical Course of Hodgkin Lymphoma. Blood, 2010, 116, 4826-4826.	1.4	0
187	The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study. Blood, 2010, 116, 992-992.	1.4	0
188	SELECTIVE INFLUENCES IN THE B-CELL RECEPTOR IMMUNOGLOBULIN HEAVY AND LIGHT CHAIN IN HAIRY CELL LEUKEMIA. Journal of the Siena Academy of Sciences, 2009, 1, .	0.0	0
189	SELECTIVE INFLUENCES IN THE B-CELL RECEPTOR IMMUNOGLOBULIN HEAVY AND LIGHT CHAIN IN HAIRY CELL LEUKEMIA. Journal of the Siena Academy of Sciences, 2009, 1, 18.	0.0	0
190	Combination therapies to improve the long-term outcome in hairy cell leukemia. Leukemia and Lymphoma, 2009, 50, 18-22.	1.3	11
191	The Prognostic Value of <i>TP53</i> Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness. Clinical Cancer Research, 2009, 15, 995-1004.	7.0	284
192	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. Clinical Cancer Research, 2009, 15, 4415-4422.	7.0	189
193	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. British Journal of Haematology, 2009, 144, 492-506.	2.5	106
194	Longâ€•term followâ€•up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16â€•years from diagnosis. British Journal of Haematology, 2009, 145, 733-740.	2.5	229
195	The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai O chronic lymphocytic leukaemia and is recapitulated by biological risk factors. British Journal of Haematology, 2009, 146, 64-75.	2.5	136
196	Defining origins of malignant B cells: a new circulating normal human IgM+D+ B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population. Leukemia, 2009, 23, 2075-2080.	7.2	16
197	Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. Journal of Translational Medicine, 2009, 7, 1.	4.4	74
198	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. Journal of Translational Medicine, 2009, 7, 76.	4.4	41

#	ARTICLE	IF	CITATIONS
199	Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. <i>Blood</i> , 2009, 114, 4696-4702.	1.4	114
200	Impaired Expression of p66Shc, a Novel Regulator of B-Cell Survival, in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 801-801.	1.4	0
201	Chronic Lymphocytic Leukemia Subset Expressing Mutated IGHV3-23 Has Peculiar Clinical and Biological Features.. <i>Blood</i> , 2009, 114, 1256-1256.	1.4	1
202	Angiopoietin-2 Plasma Dosage Predicts Time to First Treatment (TTFT) and Overall Survival (OS) in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 1260-1260.	1.4	0
203	The Normal IGHV1-69-derived B Cell Repertoire Contains "Stereotypic" Patterns Characteristic of Unmutated CLL.. <i>Blood</i> , 2009, 114, 4370-4370.	1.4	0
204	TP53 Mutations, the Most Frequent Genetic Lesion in Richter Syndrome, Represent An Independent Predictor of Survival Post Transformation.. <i>Blood</i> , 2009, 114, 670-670.	1.4	3
205	B-Cell Chronic Lymphocytic Leukemia Cells Exposed to the Non-Genotoxic p53 Activator Nutlin-3 Are Characterized by a Specific Gene Expression Signature.. <i>Blood</i> , 2009, 114, 4374-4374.	1.4	0
206	Host Genetic Background and Risk of Richter Syndrome: The Genotype of LRP4 Is An Independent Predictor of Chronic Lymphocytic Leukemia Transformation to Aggressive Lymphoma.. <i>Blood</i> , 2009, 114, 2340-2340.	1.4	0
207	The Host Genetic Background of DNA Repair Mechanisms Represents An Independent Predictor of Progression and Survival in Diffuse Large B-Cell Lymphoma Treated with R-CHOP.. <i>Blood</i> , 2009, 114, 442-442.	1.4	0
208	High Resolution Array-CGH Provides New Insights Into the Prognosis of Chronic Lymphocytic Leukemia (CLL): Is 8p Loss Worse Than 17p Loss?.. <i>Blood</i> , 2009, 114, 2339-2339.	1.4	0
209	Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.. <i>Blood</i> , 2009, 114, 760-760.	1.4	0
210	Identification of New Recurrent Multiple Small Interstitial Deletions Affecting Genes Coding for Kinases in Chronic Lymphocytic Leukemia (CLL): a New Pathogenic Mechanism?.. <i>Blood</i> , 2009, 114, 672-672.	1.4	0
211	Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. <i>Hematological Oncology</i> , 2008, 26, 247-251.	1.7	36
212	Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10. <i>Leukemia</i> , 2008, 22, 224-226.	7.2	8
213	High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. <i>British Journal of Haematology</i> , 2008, 141, 622-630.	2.5	32
214	Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. <i>British Journal of Haematology</i> , 2008, 142, 529-537.	2.5	78
215	Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. <i>British Journal of Haematology</i> , 2008, 143, 532-536.	2.5	58
216	Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. <i>Haematologica</i> , 2008, 93, 697-705.	3.5	32

#	ARTICLE	IF	CITATIONS
217	Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone Lymphomas. <i>Blood</i> , 2008, 112, 622-622.	1.4	1
218	Equivalent Efficacy and Lower Toxicity of Subcutaneous Cladribine at Reduced Doses (Five versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Italian Cooperative Group on Hcl. <i>Blood</i> , 2008, 112, 3174-3174.	1.4	0
219	Genome Wide-DNA Profiling of Richterâ€™s Syndrome-Diffuse Large B-Cell Lymphoma (RS-DLBCL): Differences with De Novo DLBCL and Possible Mechanisms of Transformation from Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2008, 112, 2067-2067.	1.4	0
220	Multivariate Analysis of Prognostic Factors in CLL: A Study on 431 Patients Showing Usefulness of Novel Biological and Old Clinical Parameters in Predicting Shorter Survival: An Italian Multicentric Study. <i>Blood</i> , 2008, 112, 3143-3143.	1.4	0
221	Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Blood</i> , 2008, 112, 778-778.	1.4	0
222	The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Is Independent of del17p13: Implications for Overall Survival and Chemorefractoriness. <i>Blood</i> , 2008, 112, 3137-3137.	1.4	0
223	Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients. <i>Acta Haematologica</i> , 2007, 118, 7-9.	1.4	3
224	Comprehensive characterization of IGHV3-21â€™expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007, 109, 2989-2998.	1.4	62
225	Complete molecular remission induced by concomitant Cladribine â€™ Rituximab treatment in a case of multi-resistant Hairy Cell Leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 2441-2443.	1.3	18
226	The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. <i>Cancer</i> , 2007, 110, 2240-2247.	4.1	47
227	Identification of New Recurrent Lesions and Clinical Subsets by Genome-Wide DNA Profiling in Chronic Lymphocytic Leukemia with 17p Deletion.. <i>Blood</i> , 2007, 110, 4696-4696.	1.4	0
228	Genome-Wide DNA Profiling Identifies a Stable Profile Although with Aberrations Targeting the Fibroblast Growth Factor Pathway in Hairy Cell Leukemia.. <i>Blood</i> , 2007, 110, 4698-4698.	1.4	0
229	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. <i>Blood</i> , 2007, 110, 3089-3089.	1.4	0
230	Low Dose Oral Fludarabine Plus Cyclophosphamide in Elderly Patients with Untreated and Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007, 110, 2055-2055.	1.4	0
231	IgM+ B-Cells Lacking CD27 Expression Display Somatic Mutated Ig VH Genes and Define a New Memory Population.. <i>Blood</i> , 2007, 110, 2630-2630.	1.4	1
232	Emerging drugs in chronic myelogenous leukaemia. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 651-664.	2.4	12
233	Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. <i>Leukemia</i> , 2006, 20, 142-143.	7.2	16
234	Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 449, 320-327.	2.8	10

#	ARTICLE	IF	CITATIONS
235	Hairy Cell Leukemias (HCL) with Unmutated V-Genes Have a Poorer Response to Single Agent 2CdA Than HCL with Mutated V-Genes.. Blood, 2006, 108, 2327-2327.	1.4	2
236	LAT Down-Regulation in T Lymphocytes from B-Cell Chronic Lymphocytic Leukemia: A Possible Mechanism for T Cell Incompetence.. Blood, 2006, 108, 3882-3882.	1.4	0
237	Thrombotic Thrombocytopenic Purpura Secondary to an Occult Adenocarcinoma. Oncologist, 2005, 10, 299-300.	3.7	10
238	Massive intravascular hemolysis: a fatal complication of <i>Clostridium perfringens</i> septicemia in a patient with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2005, 46, 793-793.	1.3	12
239	Effect of a p210 multi-peptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet, The, 2005, 365, 657-662.	13.7	221
240	Effect of a p210 multi-peptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet, The, 2005, 365, 657-662.	13.7	138
241	Control of Residual Disease in Imatinib Treated Chronic Myeloid Leukemia Patients with Peptide Vaccinations: 2 Years Follow up of CMLVAX100 Trial.. Blood, 2005, 106, 167-167.	1.4	10
242	Phase II Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen as Induction Therapy Plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients.. Blood, 2005, 106, 4613-4613.	1.4	0
243	VH and VL Genes in Hairy Cell Leukemia Reveal a Dynamic On-Going Modification of the Surface B-Cell Receptor.. Blood, 2005, 106, 287-287.	1.4	13
244	ZAP-70 Expression in T Cells of B-Cell Chronic Lymphocytic Leukaemia: Correlation with Negative Prognostic Factors of the Disease.. Blood, 2005, 106, 4998-4998.	1.4	0
245	Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies. Haematologica, 2005, 90, 266-8.	3.5	32
246	Towards the pharmacotherapy of hairy cell leukaemia. Expert Opinion on Pharmacotherapy, 2004, 5, 1523-1533.	1.8	13
247	Trisomy 12 and t(14;22)(q32;q11) in a Patient with B-cell Chronic Lymphocytic Leukemia. Hematology, 2004, 9, 405-407.	1.5	4
248	Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. The Hematology Journal, 2004, 5, 472-474.	1.4	17
249	Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency. British Journal of Haematology, 2004, 124, 604-609.	2.5	7
250	Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a VH-gene is unmutated?. Leukemia, 2004, 18, 882-883.	7.2	18
251	Molecular Cytogenetic Analysis of B-CLL Patients with Aggressive Disease. Hematology, 2004, 9, 383-385.	1.5	8
252	Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood, 2004, 104, 3312-3317.	1.4	84

#	ARTICLE	IF	CITATIONS
253	Origins of the malignant clone in typical Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 136-141.	2.2	37
254	Low-grade non Hodgkin's lymphomas in the elderly: impact of a low-dose fludarabine-based combination regimen (mini-FLEC). <i>Haematologica</i> , 2003, 88, 358-60.	3.5	0
255	Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. <i>Blood</i> , 2002, 100, 1505-1507.	1.4	105
256	Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses. <i>Immunology</i> , 2002, 107, 39-45.	4.4	20
257	Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. <i>Blood</i> , 2002, 100, 1505-7.	1.4	25
258	Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. <i>Blood</i> , 2001, 98, 1174-1181.	1.4	77
259	The occurrence and significance of V gene mutations in B cell-derived human malignancy. <i>Advances in Cancer Research</i> , 2001, 83, 81-116.	5.0	95
260	Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. <i>Haematologica</i> , 2001, 86, 1046-50.	3.5	73
261	Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. , 2000, 27, 177-182.		9
262	Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas. <i>Haematologica</i> , 1999, 84, 716-20.	3.5	9
263	CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland. <i>Haematologica</i> , 1999, 84, 946-8.	3.5	10
264	Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype. <i>Haematologica</i> , 1998, 83, 853-4.	3.5	2
265	Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. <i>Leukemia</i> , 1997, 11, 629-632.	7.2	39
266	High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. <i>Leukemia</i> , 1997, 11, 2075-2078.	7.2	113
267	2-Deoxychlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. <i>European Journal of Haematology</i> , 1997, 58, 46-50.	2.2	26
268	B-cell chronic lymphocytic leukemia. , 0, , 786-792.		0